Skip to content
God Of Sound – Lifestyle
Author:
Newron Pharmaceuticals SpA
Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study
September 25, 2026
Newron presents H1 2026 results and provides corporate update
September 22, 2026
Newron Secures EUR 5.5M Financing for Evenamide Phase 3 Program
September 8, 2026
Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
September 2, 2026